Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2026 | Health-related QoL in patients with high-risk APL treated with arsenic trioxide: APOLLO trial

Fabio Efficace • 13 Jun 2026
EHA 2026
Acute Promyelocytic Leukemia Leukemia Rare Diseases Arsenic trioxide
APOLLO

Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy, comments on the APOLLO trial (NCT02688140), which evaluated arsenic trioxide versus standard chemotherapy in patients with high-risk acute promyelocytic leukemia (APL). Dr Efficace discusses quality-of-life (QoL) outcomes from this trial, including fatigue. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Fabio Efficace

Prognostic value of pre-treatment health-related QoL indicators in AML: analysis from EORTC AML21
0:59
Prognostic value of pre-treatment health-related QoL indicators in AML: analysis from EORTC AML21
Fabio Efficace • 12 Jun 2026
The role of physical fitness and PROs in frailty assessment for R/R multiple myeloma
1:36
The role of physical fitness and PROs in frailty assessment for R/R multiple myeloma
Fabio Efficace • 8 Dec 2025
The prognostic value of patient-reported fatigue in aggressive B-cell lymphoma treated with CAR-T
1:14
The prognostic value of patient-reported fatigue in aggressive B-cell lymphoma treated with CAR-T
Fabio Efficace • 8 Dec 2025
HRQoL trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy
1:30
HRQoL trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy
Fabio Efficace • 8 Dec 2025

Related Videos

Insights from the AIEOP-BFM ALL trial: could blinatumomab replace high-dose chemotherapy in HR ALL?
1:48
Insights from the AIEOP-BFM ALL trial: could blinatumomab replace high-dose chemotherapy in HR ALL?
Martin Schrappe • 11 Jun 2026
Guidance for community oncologists treating patients with relapsed IDH1-mutated AML
0:56
Guidance for community oncologists treating patients with relapsed IDH1-mutated AML
Agnieszka Wierzbowska • 12 Jun 2026
Addressing underrecognized symptoms and quality-of-life issues in hematologic malignancies
2:25
Addressing underrecognized symptoms and quality-of-life issues in hematologic malignancies
Esther Oliva • 25 Jun 2026
Q-TWiST analysis from the QUANTUM-First trial: evaluating quality-adjusted survival in AML
1:45
Q-TWiST analysis from the QUANTUM-First trial: evaluating quality-adjusted survival in AML
Esther Oliva • 25 Jun 2026
The content of VJHemOnc is intended for healthcare professionals